This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_OROPHARYNG_EXALLC for full statistics.
Malignant neoplasm of oropharyng
C3_OROPHARYNG
oropharynx cancer: A primary or metastatic malignant neoplasm that affects the oropharynx.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
51 |
4. Check minimum number of eventsNone |
51 |
5. Include endpointsNone |
51 |
6. Filter based on genotype QC (FinnGen only) |
51 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of oropharyng
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of oropharynx, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of oropharynx
- Malignant neoplasm of oropharynx, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of head and neck
- Malignant neoplasm of head and neck, excluding all cancers (controls excluding all cancers)
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 51 | 14 | 37 |
| Unadjusted period prevalence (%) | 0.01 | 0.00 | 0.02 |
| Median age at first event (years) | 67.50 | 65.96 | 68.08 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 50
- Matched controls
- 502
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
JDB10
NOMESCO Finland
Percutaneous gastrostomy
259.6
33.4
31
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
179.7
31.2
30
*
130
Kela drug reimbursment
Malignant tumour
42.7
27.5
38
34
R4190
NOMESCO Finland
Nutritional therapy
68.7
22.6
25
7
8070/3-C10.9
ICD-O-3
Squamous cell carcinoma, NOS, of oropharynx, NOS
+∞
21.4
19
*
C10.3
ICD-10 Finland
Malignant neoplasm: Posterior wall of oropharynx
+∞
18.9
17
*
N02AA05
ATC
oxycodone; systemic
19.4
18.7
33
45
WF002
NOMESCO Finland
Radical radiotherapy
26.4
18.7
27
21
A03FA01
ATC
metoclopramide; systemic, rectal
15.7
16.9
34
59
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
59.3
16.9
19
5
UJC01
NOMESCO Finland
Scopy of lower throat
208.5
15.4
15
*
YA1CD
NOMESCO Finland
Very extensive CT examination of head and neck for dose design of radiotherapy
+∞
14.2
13
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
14.2
13
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
85.6
12.3
13
*
A04AA01
ATC
ondansetron; systemic, rectal
16.8
11.2
18
16
C10.0
ICD-10 Finland
Malignant neoplasm: Vallecula
+∞
10.8
10
*
GBB00
NOMESCO Finland
Tracheostomy
51.3
10.5
12
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
20.7
10.3
15
10
C10.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of oropharynx
+∞
9.7
9
*
SAA03
NOMESCO Finland
Extended examination of mouth
6.9
9.4
34
117
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
12.2
9.3
17
20
ENA10
NOMESCO Finland
Biopsy of pharynx
+∞
8.6
8
*
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
+∞
8.6
8
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
17.0
8.4
13
10
EBA15
NOMESCO Finland
Extraction of large number of teeth
14.4
8.4
14
13
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
6.0
8.2
31
107
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
11.7
7.7
14
16
C01
ICD-10 Finland
Malignant neoplasm of base of tongue
93.4
7.6
8
*
H02AB02
ATC
dexamethasone; systemic
8.3
7.5
17
29
D10.9
ICD-10 Finland
Benign neoplasm: Pharynx, unspecified
+∞
7.5
7
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
7.5
7
*
GDA98
NOMESCO Finland
Other bronchoscopic incision, excision of lesion or repair of lung
+∞
7.5
7
*
C10.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of oropharynx
+∞
7.5
7
*
A06AD11
ATC
lactulose; oral
8.0
7.3
17
30
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
8.5
7.2
16
26
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
9.2
7.2
15
22
A02BC05
ATC
esomeprazole; systemic
5.0
6.8
34
149
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
8.8
6.6
14
21
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
79.6
6.6
7
*
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
31.0
6.4
8
*
8070/3-C10.3
ICD-O-3
Squamous cell carcinoma, NOS, of posterior wall of oropharynx
+∞
6.4
6
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
17.9
6.2
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
30
69
9.13
14.55
9.1
3.5
0.7
0.8
mmol/l
2.51
30
64
22
85
3.79
4.97
2.5
2.2
—
—
—
0
0
33
174
3.54
4.51
4.6
3.9
—
—
—
0
0
28
143
3.12
3.86
9.4
4.1
2.4
2.3
mmol/l
0.65
28
125
11
35
3.73
3.14
1.3
1.2
—
—
—
0
0
37
246
2.84
2.81
16.5
11.7
4.6
4.3
e9/l
0.32
32
209
17
80
2.69
2.54
5.4
3.1
2.5
2.4
mmol/l
1.47
17
67
35
239
2.48
2.32
11.7
7.1
9.5
12.1
umol/l
1.50
35
226
23
136
2.26
2.06
3.8
3.4
32.9
31.3
u/l
0.12
23
129
8
167
0.38
1.95
4.1
4.3
—
—
—
0
0
13
62
2.47
1.85
6.2
4.9
1.0
1.0
mmol/l
0.21
13
57
9
38
2.66
1.55
1.2
1.5
—
—
—
0
0
27
187
1.94
1.48
8.2
6.4
1.2
1.2
mmol/l
0.68
27
167
28
201
1.87
1.34
10.8
6.8
1.2
1.2
mmol/l
0.43
28
171
5
18
2.96
1.31
1.8
2.8
—
—
—
0
0
13
73
2.05
1.25
2.5
2.5
0.3
2.3
e6/l
—
7
40
33
256
1.82
1.17
8.7
5.0
7.1
6.9
mmol/l
0.25
33
240
6
118
0.44
1.12
1.8
1.7
1.4
1.3
mmol/l
—
6
97
42
459
0.52
1.01
17.3
11.1
26.9
25.7
u/l
0.16
42
440
13
80
1.84
0.96
2.2
1.9
—
—
—
0
0
13
81
1.81
0.92
2.5
2.3
1.0
1.3
e6/l
—
7
47
10
60
1.83
0.79
2.5
1.6
—
—
—
0
0
5
25
2.11
0.75
2.2
1.3
—
—
—
0
0
42
452
0.60
0.75
34.5
18.5
71.2
82.5
umol/l
2.56
42
452
10
63
1.73
0.68
2.5
1.7
—
—
—
0
0
5
86
0.54
0.63
1.0
1.8
735.6
433.3
pmol/l
—
5
75
15
198
0.66
0.62
1.8
4.8
20.2
21.4
%
—
5
100
39
346
1.54
0.57
14.2
8.1
79.5
79.4
u/l
0.01
39
324
5
32
1.62
0.43
19.0
6.8
29.4
24.8
mmol/l
—
5
32
0
15
0.00
0.42
0.0
1.0
—
0.0
—
0
15
5
78
0.60
0.39
1.2
1.2
—
0.8
—
0
19
5
40
1.28
0.23
2.0
2.7
3.6
8.4
ug/l
—
5
35
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
15
173
0.81
0.21
3.1
3.0
—
—
—
0
0
16
138
1.23
0.21
4.1
2.5
36.9
55.0
u/l
2.48
16
133
17
148
1.22
0.20
2.4
2.3
78.7
76.2
nmol/l
0.09
17
130
17
156
1.13
0.09
1.8
1.9
93.1
84.1
pmol/l
—
7
73
5
61
0.80
0.09
5.4
10.2
—
—
—
0
0
14
131
1.09
0.04
2.1
2.2
93.4
328.8
u/l
1.05
14
124
41
403
1.09
0.02
25.5
14.5
89.0
78.7
ml/min/173m2
3.50
34
334
21
216
0.95
0.00
2.6
2.4
—
—
—
0
0
14
141
0.99
0.00
3.3
2.6
0.4
0.5
e6/l
—
8
110
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
13.8
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
75.2
—
0
6
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_OROPHARYNG – Malignant neoplasm of oropharyng
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).